EDAP's Focal One HIFU device approved by Health Canada

BERKELEY, CA USA (Press Release) - January 9, 2015 - (GLOBE NEWSWIRE) -- EDAP TMS SA, the global leader in therapeutic ultrasound, today announced that its Focal One HIFU device has been approved by Health Canada. With this approval, the Company is able to market the Focal One device for the treatment of prostate cancer in Canada.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "Health Canada approval of Focal One, our revolutionary tool for the focal treatment of prostate cancer, represents an important milestone for EDAP. Moreover, this is the first regulatory approval for our Focal One device in the Americas, and a key step forward in our overall regulatory strategy as we work to expand Focal One's global footprint and bring our innovative cancer therapies to a growing number of patients worldwide."

Oczachowski continued: "In the 18 months since we received EU marketing approval, the enthusiastic response from the European urology community has validated our belief in the potential of focal therapy for prostate cancer and, more specifically, our Focal One system. In a relatively short time, the technology has been adopted by some of Europe's leading prostate cancer Hospitals. We look forward to a similar reception as we establish our North American presence via the Canadian market."

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In March 2013, the Company introduced a new innovative HIFU device, the Focal One® dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit www.edap-tms.com, and www.hifu-planet.com.

CONTACT:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72

###

EDAP TMS SA

[ PRESS RELEASE ]

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe